Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry

Alfonso Ielasi, Elisabetta Moscarella, Antonio Mangieri, Francesco Giannini, Didier Tchetchè, Won Keun Kim, Jean Malte Sinning, Uri Landes, Ran Kornowski, Ole De Backer, Georg Nickenig, Chiara De Biase, Lars Søndergaard, Federico De Marco, Francesco Bedogni, Marco Ancona, Matteo Montorfano, Damiano Regazzoli, Giulio Stefanini, Stefan ToggweilerCorrado Tamburino, Sebastiano Immè, Giuseppe Tarantini, Horst Sievert, Ulrich Schäfer, Jörg Kempfert, Jochen Wöehrle, Azeem Latib, Paolo Calabrò, Massimo Medda, Maurizio Tespili, Antonio Colombo

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Although bicuspid aortic valve (BAV) is not considered a “sweet spot” to trans-catheter aortic valve replacement (TAVR), a certain number of BAV underwent TAVR. Whether BAV phenotype affects outcomes following TAVR remains debated. We aimed at evaluating the impact of BAV phenotype on procedural and clinical outcomes after TAVR using new generation trans-catheter heart valves (THVs). Methods: patients included in the BEAT registry were classified according to the BAV phenotype revealed at multi-slice computed tomography (MSCT) in type 0 (no raphe) vs. type 1 (1 raphe). Primary end-point was Valve Academic Research Consortium–2 (VARC-2) device success. Secondary end-points included procedural complications, rate of permanent pacemaker implantation, clinical outcomes at 30-day and 1-year. Results: Type 0 BAV was present in 25(7.1%) cases, type 1 in 218(61.8%). Baseline characteristics were well balanced between groups. Moderate-severe aortic valve calcifications at MSCT were less frequently present in type 0 vs. type 1 (52%vs.71.1%,p = 0.05). No differences were reported for THV type, size, pre and post-dilation between groups. VARC-2 success tended to be lower in type 0 vs. type 1 BAV (72%vs86.7%;p = 0.07). Higher rate of mean transprosthetic gradient ≥20 mmHg was observed in type 0 vs. type 1 group (24%vs6%,p = 0.007). No differences were reported in the rate of post-TAVR moderate-severe aortic regurgitation and clinical outcomes between groups. Conclusions: Our study confirms TAVR feasibility in both BAV types, however a trend toward a lower VARC-2 device success and a higher rate of mean transprosthetic gradient ≥20 mmHg was observed in type 0 vs. type 1 BAV.

Original languageEnglish (US)
Pages (from-to)109-114
Number of pages6
JournalInternational Journal of Cardiology
Volume325
DOIs
StatePublished - Feb 15 2021

Keywords

  • BAV morphology
  • Bicuspid aortic valve
  • Severe aortic stenosis
  • Trans-catheter valve replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry'. Together they form a unique fingerprint.

Cite this